Novartis axes asthma drug fevipiprant after more trial woes

It’s nearly always bad news when pharma companies provide an “update” about a trial – and the statement today from Novartis about its asthma drug fevipiprant must make bleak reading for all

GSK leanest with R&D spend in big pharma - but gets bang for...

GlaxoSmithKline’s CEO Emma Walmsley has made great play of her company’s new approach to R&D under the leadership of its guru Hal Barron.

Forendo works with Novartis in liver disease, possibly targe...

Finland’s Forendo Pharma has signed a deal with Novartis aimed at identifying novel drugs for treatment of chronic liver diseases, with the potentially lucrative fatty liver disease known a

BMS preps filings for leukaemia maintenance therapy CC-486

Sanofi axes diabetes R&D, focuses on 'transformative' therap...

Take a look at Sanofi’s balance sheet and it’s obvious which way the wind is blowing – sales in its once mighty diabetes franchise are sliding, while newer medicines such as its eczema and

LentiGlobin gene therapy for sickle cell on course for filin...